APA (7th ed.) Citation

Gulick, R. M., Su, Z., Flexner, C., Hughes, M. D., Skolnik, P. R., Wilkin, T. J., . . . Kuritzkes, D. R. (2007). Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. The Journal of infectious diseases, 196(2), 304-312. https://doi.org/10.1086/518797

Chicago Style (17th ed.) Citation

Gulick, Roy M., et al. "Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211." The Journal of Infectious Diseases 196, no. 2 (2007): 304-312. https://doi.org/10.1086/518797.

MLA (9th ed.) Citation

Gulick, Roy M., et al. "Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211." The Journal of Infectious Diseases, vol. 196, no. 2, 2007, pp. 304-312, https://doi.org/10.1086/518797.